1. Home
  2. THCH vs INAB Comparison

THCH vs INAB Comparison

Compare THCH & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TH International Limited Ordinary shares

THCH

TH International Limited Ordinary shares

HOLD

Current Price

$2.01

Market Cap

65.0M

Sector

Finance

ML Signal

HOLD

Logo IN8bio Inc.

INAB

IN8bio Inc.

HOLD

Current Price

$1.47

Market Cap

15.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
THCH
INAB
Founded
2018
2016
Country
China
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
65.0M
15.6M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
THCH
INAB
Price
$2.01
$1.47
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
5.9K
54.9K
Earning Date
04-14-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.69
$0.12
52 Week High
$3.25
$4.20

Technical Indicators

Market Signals
Indicator
THCH
INAB
Relative Strength Index (RSI) 49.24 42.07
Support Level $2.01 $1.35
Resistance Level $2.31 $1.69
Average True Range (ATR) 0.18 0.09
MACD -0.00 0.00
Stochastic Oscillator 70.83 20.72

Price Performance

Historical Comparison
THCH
INAB

About THCH TH International Limited Ordinary shares

TH International Ltd is the exclusive master franchisee in China for Tim Hortons, a world-wide coffee and bakery shop brand. Through the Tim Hortons brand, the firm offers freshly brewed coffee, tea, and other beverages, bakery & sides, and sandwiches. The Company operated under a single reportable segment, Tim Hortons. The company's revenue is derived from sales of food, beverages, and packaged products by company-owned and operated stores, franchise fees, and revenue from other franchise support activities. Its geographic revenue is derived from operations in the PRC.

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

Share on Social Networks: